Keywords
insuficiência cardíaca
tratamento
How to Cite
Abstract
This study aims to use SGLT2 inhibitors in the treatment of heart failure, focusing on their impact on mortality and hospitalizations. The research was conducted using the PubMed index with the terms "SGLT2 inhibitors AND heart failure with reduced ejection fraction AND mortality reduction." The results indicate that this serious condition requires continuous monitoring involving various measures, such as sodium-glucose cotransporter type 2 (SGLT2) inhibitors, which demonstrate a 26% reduction in cardiovascular risk for patients using Dapagliflozin. Additionally, although recommended as standard treatment for patients and with evidence showing significant reductions in mortality and hospitalizations due to heart failure, the mechanisms of action of SGLT2 inhibitors are not fully understood. Thus, there is a need for more detailed and specific analysis of these mechanisms to better understand the clinical effects associated with them. Despite being primarily developed for the treatment of Type 2 Diabetes Mellitus, a reduction in adverse clinical outcomes has been observed in patients with heart failure with reduced ejection fraction (HFrEF).
References
AHMAD, M. et al. Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials. PMCID: PMC9170566, 2021.
BERG, D. D. et al. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. PMCID: PMC7890451, 2021.
BOYANG, Z. et al. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis. PubMed: 36125813, 2022.
BRITO, F. P. et al. Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential. PMCID: PMC7242490, 2020.
DOEHNER, W. et al. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. PMCID: PMC9492270, 2022.
ESPINOZA, J. et al. Updates in pharmacotherapy of heart failure with reduced ejection fraction. PubMed: 33850913, 2021.
FATIMA, R. et al. Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management. PubMed: 37908957, 2023.
GENUARDI, M. et al. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction. PubMed: 33779401, 2021.
JI, S. et al. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials. PubMed: 37111578, 2023.
JENSEN, J. et al. Sodium-glucose co-transporter-2 inhibitors in heart failure with reduced ejection fraction: Current evidence and future perspectives. PubMed: 35510595, 2022.
LORENZI, L. M. et al. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction. PubMed: 36660013, 2023.
MUSCOLI, C. et al. The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective. PubMed: 36015359, 2022.
PANDEY, K. et al. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis. PubMed: 35112512, 2022.
SOEIRO, Alexandre de M.; LEAL, Tatiana de Carvalho A T.; ACCORSI, Tarso Augusto D.; et al. Manual da residência em cardiologia. 2nd ed. Barueri: Manole, 2021. E-book. p.402. ISBN 9786555766646.
TOMASONI, D. et al. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. PubMed: 34894038, 2022.
USMAN, M. et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. PubMed: 38768620, 2024.
ZANNAD, F. et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. PubMed: 32877652, 2020.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Alaise Clementino Guedes , Maria Júlia Moraes Assunção, Uiara Régia Soares da Silva, Marina de Araújo Montenegro, Luciano Duque Portela, Ana Carolina Clementino Guedes de Almeida, Davi Ricardo Santos Costa de Oliveira, Gabriel Nobrega Câmara, Vitor Paim Ferreira Câmada, Celso Henrique de Araújo Alves, Bianca Moreira Marques, Yasmin
